Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Sep 28

PMID 34576242

Citations 8

Authors

Valentina La Cognata

Maria Guarnaccia

Giovanna Morello

Martino Ruggieri

Agata Polizzi

Sebastiano Cavallaro

Affiliations

Soon will be listed here.

Abstract

Lysosomal storage diseases (LSDs) are a heterogeneous group of approximately 70 monogenic metabolic disorders whose diagnosis represents an arduous challenge for clinicians due to their variability in phenotype penetrance, clinical manifestations, and high allelic heterogeneity. In recent years, the approval of disease-specific therapies and the rapid emergence of novel rapid diagnostic methods has opened, for a set of selected LSDs, the possibility for inclusion in extensive national newborn screening (NBS) programs. Herein, we evaluated the clinical utility and diagnostic validity of a targeted next-generation sequencing (tNGS) panel (called NBS_LSDs), designed ad hoc to scan the coding regions of six genes (, , , , , ) relevant for a group of LSDs candidate for inclusion in national NBS programs (MPSI, Pompe, Fabry, Krabbe, Niemann Pick A-B and Gaucher diseases). A standard group of 15 samples with previously known genetic mutations was used to test and validate the entire flowchart. Analytical accuracy, sensitivity, and specificity, as well as turnaround time and costs, were assessed. Results showed that the Ion AmpliSeq and Ion Chef System-based high-throughput NBS_LSDs tNGS panel is a fast, accurate, and cost-effective process. The introduction of this technology into routine NBS procedures as a second-tier test along with primary biochemical assays will allow facilitating the identification and management of selected LSDs and reducing diagnostic delay.

Citing Articles

Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease.

Yao F, Hao N, Li D, Zhang W, Zhou J, Qiu Z Hum Genomics. 2024; 18(1):133.

PMID: 39609713 PMC: 11603755. DOI: 10.1186/s40246-024-00697-3.

Second-tier strategies in newborn screening - potential and limitations.

Gramer G, Hoffmann G Med Genet. 2024; 34(1):21-28.

PMID: 38836011 PMC: 11006380. DOI: 10.1515/medgen-2022-2117.

Detection of Single-Nucleotide and Copy Number Defects Underlying Hyperphenylalaninemia by Next-Generation Sequencing.

Tendi E, Morello G, Guarnaccia M, La Cognata V, Petralia S, Messina M Biomedicines. 2023; 11(7).

PMID: 37509538 PMC: 10377317. DOI: 10.3390/biomedicines11071899.

Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B).

Geberhiwot T, Wasserstein M, Wanninayake S, Bolton S, Dardis A, Lehman A Orphanet J Rare Dis. 2023; 18(1):85.

PMID: 37069638 PMC: 10108815. DOI: 10.1186/s13023-023-02686-6.

Detection of Structural Variants by NGS: Revealing Missing Alleles in Lysosomal Storage Diseases.

La Cognata V, Cavallaro S Biomedicines. 2022; 10(8).

PMID: 36009380 PMC: 9405548. DOI: 10.3390/biomedicines10081836.

References

Smolders S, Van Broeckhoven C . Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis. Acta Neuropathol Commun. 2020; 8(1):63. PMC: 7201634. DOI: 10.1186/s40478-020-00935-4. View

Kingma S, Bodamer O, Wijburg F . Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015; 29(2):145-57. DOI: 10.1016/j.beem.2014.08.004. View

Wang R, Bodamer O, Watson M, Wilcox W . Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011; 13(5):457-84. DOI: 10.1097/GIM.0b013e318211a7e1. View

Schuchman E . Two new mutations in the acid sphingomyelinase gene causing type a Niemann-pick disease: N389T and R441X. Hum Mutat. 1995; 6(4):352-4. DOI: 10.1002/humu.1380060412. View

Zanetti A, DAvanzo F, Bertoldi L, Zampieri G, Feltrin E, De Pascale F . Setup and Validation of a Targeted Next-Generation Sequencing Approach for the Diagnosis of Lysosomal Storage Disorders. J Mol Diagn. 2020; 22(4):488-502. DOI: 10.1016/j.jmoldx.2020.01.010. View

Fleige T, Burggraf S, Czibere L, Haring J, Gluck B, Keitel L . Next generation sequencing as second-tier test in high-throughput newborn screening for nephropathic cystinosis. Eur J Hum Genet. 2019; 28(2):193-201. PMC: 6974606. DOI: 10.1038/s41431-019-0521-3. View

Burlina A, Polo G, Salviati L, Duro G, Zizzo C, Dardis A . Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2017; 41(2):209-219. DOI: 10.1007/s10545-017-0098-3. View

Boustany R . Lysosomal storage diseases--the horizon expands. Nat Rev Neurol. 2013; 9(10):583-98. DOI: 10.1038/nrneurol.2013.163. View

La Cognata V, Guarnaccia M, Polizzi A, Ruggieri M, Cavallaro S . Highlights on Genomics Applications for Lysosomal Storage Diseases. Cells. 2020; 9(8). PMC: 7465195. DOI: 10.3390/cells9081902. View

10.

Anderson S . Newborn Screening for Lysosomal Storage Disorders. J Pediatr Health Care. 2018; 32(3):285-294. DOI: 10.1016/j.pedhc.2017.04.016. View

11.

Malaga D, Brusius-Facchin A, Siebert M, Pasqualim G, Saraiva-Pereira M, de Souza C . Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders. Genet Mol Biol. 2019; 42(1 suppl 1):197-206. PMC: 6687342. DOI: 10.1590/1678-4685-GMB-2018-0092. View

12.

Hendrix M, Cuthbert C, Cordovado S . Assessing the Performance of Dried-Blood-Spot DNA Extraction Methods in Next Generation Sequencing. Int J Neonatal Screen. 2020; 6(2). PMC: 7278269. DOI: 10.3390/ijns6020036. View

13.

Ki C . Recent Advances in the Clinical Application of Next-Generation Sequencing. Pediatr Gastroenterol Hepatol Nutr. 2021; 24(1):1-6. PMC: 7813577. DOI: 10.5223/pghn.2021.24.1.1. View

14.

Encarnacao M, Coutinho M, Silva L, Ribeiro D, Ouesleti S, Campos T . Assessing Lysosomal Disorders in the NGS Era: Identification of Novel Rare Variants. Int J Mol Sci. 2020; 21(17). PMC: 7503609. DOI: 10.3390/ijms21176355. View

15.

Boemer F, Fasquelle C, dOtreppe S, Josse C, Dideberg V, Segers K . A next-generation newborn screening pilot study: NGS on dried blood spots detects causal mutations in patients with inherited metabolic diseases. Sci Rep. 2017; 7(1):17641. PMC: 5732277. DOI: 10.1038/s41598-017-18038-x. View

16.

Gelb M . Newborn Screening for Lysosomal Storage Diseases: Methodologies, Screen Positive Rates, Normalization of Datasets, Second-Tier Tests, and Post-Analysis Tools. Int J Neonatal Screen. 2019; 4(3). PMC: 6419971. DOI: 10.3390/ijns4030023. View

17.

Schielen P, Kemper E, Gelb M . Newborn Screening for Lysosomal Storage Diseases: A Concise Review of the Literature on Screening Methods, Therapeutic Possibilities and Regional Programs. Int J Neonatal Screen. 2017; 3(2). PMC: 5515486. DOI: 10.3390/ijns3020006. View

18.

Pitcairn C, Wani W, Mazzulli J . Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. Neurobiol Dis. 2018; 122:72-82. PMC: 6138580. DOI: 10.1016/j.nbd.2018.03.008. View

19.

Gelb M, Lukacs Z, Ranieri E, Schielen P . Newborn Screening for Lysosomal Storage Disorders: Methodologies for Measurement of Enzymatic Activities in Dried Blood Spots. Int J Neonatal Screen. 2019; 5(1). PMC: 6448570. DOI: 10.3390/ijns5010001. View

20.

Platt F . Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Rev Drug Discov. 2017; 17(2):133-150. DOI: 10.1038/nrd.2017.214. View